Introduction/Background 95–99% of patients with invasive cervical cancer are positive to human papilloma virus (HPV). The objective of the current study was to evaluate the incidence of Low Risk (LR-HPV) types among women with Cervical Intra-epithelial Neoplasia 2–3 (CIN 2–3) and cervical cancer (CC).

Methodology We conducted a nested cohort study of patients diagnosed from May 2008 until October 2017 with CIN 2–3 or cervical cancer.

Results During the study period we collected clinical data on 608 women of whom 402 were with CIN 2-3 and 206 with diagnosis of cervical cancer (CC). The most common presenting symptom among CIN 2–3 patients was post-coital bleeding (33.3%) compared to post-menopausal bleeding (36.2%) among CC patients. Of patients with CIN 2-3, 90.3% were found positive to at least one type of HR-HPV, compared to 89.3% of CC patients. 4.5% of patients with CIN 2-3 and 3.9% of those with CIN2-3 were positive to only one LR-HPV, or to some of a few LR-HPV types. Among 5.2% with CIN 2-3 and 6.3% of those with CC no HPV types were detected.

Conclusion The prevalence of the LR-HPV is low but it could not be ignored due to the expected decrease in CC caused by HPV types that are included in the bi-, quadri-, and nano-valent vaccine. The CIN 2-3 and CC patients with LR-HPV types and with negative HPV are challenging the sensitivity of HPV screening that is based on HPV screening of a limited number of HR-HPV types.

Disclosure Nothing to disclose.